Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.

ASX Announcements / Neuren Pharmaceuticals Limited (ASX:NEU)

All Neuren Pharmaceuticals Limited (ASX:NEU) announcement summaries, newest first. Every summary is drawn only from the company's official ASX release.

August 2026

Neuren Pharmaceuticals Limited (ASX:NEU)
OperationsPrice Sensitive

Neuren Partner Acadia Wins EU Approval for DAYBU

Neuren said the European Commission approved DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome, a first in the EU. Acadia is Neuren's licensee.

Neuren Pharmaceuticals Limited (ASX:NEU)

8:31 am

25 Aug 2026

Neuren Pharmaceuticals Limited (ASX:NEU)
QuarterlyPrice Sensitive

Acadia Q2 DAYBUE Sales US$125m Lift Neuren Royalties

Neuren reported partner Acadia's Q2 2026 DAYBUE net sales of US$125m, up 30%, and said its own full-year 2026 royalty income is now expected at US$53-56m.

Neuren Pharmaceuticals Limited (ASX:NEU)

9:52 am

5 Aug 2026

Copyright © 2026 SureStone Capital